NCT06013618 2025-06-17Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed NeuroblastomaSun Yat-sen UniversityPhase 2 Recruiting120 enrolled
NCT00805961 2021-12-08RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBMSCRI Development Innovations, LLCPhase 2 Completed68 enrolled 8 charts